Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REVAX
- Development stage
- Preclinical
- Lead developer
- Reyon Pharmaceutical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Injection
01
Overview
REVAX is a plasmid DNA (pDNA)-based therapeutic vaccine being developed by Reyon Pharm for the treatment of liver fibrosis. As a therapeutic vaccine, it is designed to deliver genetic material into cells to induce a specific immune response or modulate biological pathways involved in the progression of fibrotic liver disease. The candidate is currently in the preclinical stage of development, leveraging Reyon Pharm's expertise in gene therapy and pDNA platforms.
Beyond the preview
Go deeper on REVAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REVAX.